drugset / Trial / NCT00024232

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

NCT00024232 ↗

Treatment

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have prostate cancer that has not responded to hormone therapy.

Timeline

Start
2001-06
Primary completion
2004-02
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject huJ591 Monoclonal antibody — Intravenous

Indications